CELLDEX THERAPEUTICS INCCLDX
ASignal's systematic analysis rates CLDX as Bearish.
Reflects the latest available analysis · analyzed Oct 21, 2026
The case on CLDX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $717.59M in total cash
- Low debt-to-equity ratio of 0.01x indicating minimal leverage risk
- High current and quick ratios (11.82x and 11.71x) suggesting solid short-term liquidity
- Severely negative operating margin at -366,468.20%
- Negative return on equity (-43.88%) and return on assets (-27.62%)
- Extremely high price-to-sales ratio (15,054.81x) and enterprise value to revenue (10,544.16x)
- Revenue growth year-over-year at -97.00%, indicating near-total revenue collapse
- Negative free cash flow of $-133.08M and operating cash flow of $-235.57M
- Forward P/E of -7.13x suggests unprofitable earnings trajectory
See the full verdict on CLDX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CLDX
Most investors never get a second opinion, let alone several. ASignal runs CLDX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.